Neuropsychological testing in the diagnosis and management of patients with dementia
https://doi.org/10.21518/2079-701X-2018-18-16-22
Abstract
The article discusses neuropsychological tests for diagnosing cognitive impairment. It presents data on the experience in using memantine (akatinol memantine) to treat dementia of various genesis. An analysis of efficacy of non-pharmacological approaches to the treatment of dementia including cognitive training is provided.
About the Author
D. A. Grishina
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Yahno NN. Cognitive disorders in the neurological clinic. Nevrologichesky Zhurnal, 2006, 11 (S1): 4–12.
2. Yakhno NN, Zakharov VV, Lokshina AB, Koberskaya NN, Mkhitaryan EA. Dementia. A practical guide for practitioners. M.: MEDpressinform, 2011. 272 p.
3. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Cognitive disorders. M.: Remedium, 2014.
4. Diagnostic and statistical manual of mental diseases. V ed. (DSM-V). London: American Psychiatric Association, 2013.
5. Yakhno NN, Zakharov VV, Koberskaya NN, Mkhitaryan EA, Grishina DA, Lokshina AB, et al. “Pre-moderate” (subjective and light) cognitive disorders. Nevrologichesky Zhurnal, 2017, 22 (4): 198–204.
6. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer report 2016: improving healthcare for people living with dementia. London: Alzheimer’s disease international, 2016.
7. Zakharov VV. All-Russian Program for the Study of Epidemiology and Therapy of Cognitive Disorders in the Elderly (“Prometheus”). Nevrologichesky Zhurnal, 2006, 11: 27–32.
8. Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Stepkina DA, Lokshina AB, Mkhitaryan EA. The prevalence of cognitive impairment in neurological diseases (analysis of specialized outpatient visits). Nevrologiya, Neyropsikhiatriya, Psikhosomatika, 2012, 2: 30–35.
9. Zakharov VV, Voznesenskaya TG. Neuropsychiatric disorders: diagnostic tests. M.: MEDpress-inform, 2013. 320 p.
10. Levin OS. Algorithms for the diagnosis and management of dementia. M.: MEDpress-inform, 2014. 192 p.
11. Stepkina DA, Zakharov VV, Yakhno NN. Syndrome of primary progressive aphasia. Nevrologichesky Zhurnal, 2014, 5: 22-28.
12. Parfenov VA, Starchin YuA, Yakhno NN. Eprosartan (Teveten) in the prevention of re-stroke and cognitive impairment. Nevrologichesky Zhurnal, 2007, 12 (1): 46–51.
13. Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. Dementia therapeutic research ed. by K. Rockwood, S. Gauthier. London, New York: Taylor a Francis, 2006: 189–212.
14. Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi Ch et al. Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Design, Development and Therapy, 2013, 7: 1359-1364.
15. Gavrilova SI. Pharmacotherapy of Alzheimer’s disease. M.: Pulse, 2003.
16. Damulin IV, Yakhno NN. Alzheimer’s disease and vascular dementia. M., 2002. 85 c.
17. Levin DA, Langa KM. Vascular cognitive impairment: disease mechanisms and treatment implications. Neurotherapeutics, 2011, 8 (3): 361–73.
18. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P. et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.
19. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement, 2011, 5: 280-292.
20. Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacological Reports, 2016, 68(1): 127-138.
21. Mark LP, Prost RW, Ulmer JL, Smith MM, Daniels DL, Strottmann JM et al. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. Amer J Neuroradiol, 2001, 22: 1813-1824.
22. Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer’s disease. Neurosci Lett, 1998, 86: 109-113.
23. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 2004, 291: 317-324.
24. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K. et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebocontrolled, multicentre trial. Lancet Neurol, 2009, 8: 613–618.
25. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke, 2002, 33: 1834–1839.
26. Petersen KA. Compliance and practical considerations in the management of Alzheimer’s disease with memantine. Eur J Neurology, 2007, 14(1): 1107.
27. Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. Efficacy of memantine in patients with non-dement cognitive disorders. The results of multicenter clinical observation. Nevrologichesky Zhurnal, 2010, 2: 52–58.
28. Parfenov VA. Early diagnosis and management of Alzheimer’s disease. Meditsinsky Sovet, 2015, 5: 28–33.
29. Mendiola-Precoma J, Berumen LC, Padilla K. Therapies for prevention and treatment of Alzheimer’s disease. BioMed research international, 2016: 17.
30. Olazaran J, Muniz R, Reisberg B et al. Benefit of cognitive-motor intervention in MCI and mild-to-moderate AD. Neurology, 2004, 63 (12): 2348–2353.
Review
For citations:
Grishina DA. Neuropsychological testing in the diagnosis and management of patients with dementia. Meditsinskiy sovet = Medical Council. 2018;(18):16-22. (In Russ.) https://doi.org/10.21518/2079-701X-2018-18-16-22
Views:
2977
Email this article 